PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Smolen, Josef S.
TI  - Tocilizumab, a Novel Monoclonal Antibody Targeting IL-6 Signaling, Significantly Reduces Disease Activity in Patients with Rheumatoid Arthritis
DP  - 2007 Sep 01
TA  - MD Conference Express
PG  - 11--11
VI  - 7
IP  - 4
4099  - http://mdc.sagepub.com/content/7/4/11.1.short
4100  - http://mdc.sagepub.com/content/7/4/11.1.full
AB  - The cytokine IL-6 plays a central role in maintaining chronic inflammation in rheumatoid arthritis (RA). Tocilizumab is the first humanized interleukin-6 receptor inhibiting monoclonal antibody and represents a novel mechanism of action to treat RA. This article presents data from the phase 3 Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders [OPTION] international study, involving 623 patients with moderate to severe RA.